ANIP
ANI PHARMACEUTICALS INCPrice
Daily candles with volume. Callouts mark insider and congressional trades, rating changes, 13F stakes, reports, catalysts, court and regulator actions, Reddit spikes and short-interest jumps. Hover one for the details (tap on phones).
- May 11 to May 13 ▼ 3 days of insider sells: $5.7M by 5 insiders, avg $78.25
- Jun 5 to Jun 12 ▼ 3 days of insider sells: $467.7K by 3 insiders, avg $80.48
- Jun 29 to Jul 2 ▼ 2 days of insider sells: $524.7K by 1 insider, avg $85.13
- Aug 10 to Aug 13 ▼ 2 days of insider sells: $281.2K by 2 insiders, avg $76.79
- Aug 25 to Aug 31 ▼ 2 days of insider sells: $608.7K by 2 insiders, avg $73.78
- Sep 11 to Sep 15 ▼ 3 days of insider sells: $490.3K by 3 insiders, avg $71.06
- Sep 23 Contract: ANI Pharmaceuticals Announces the FDA Approval of Everolim…
- Sep 23 Oppenheimer initiates
- Sep 30 ▼ Short interest jumps 40.2% to 3.49M
- Oct 13 to Oct 15 ▼ 2 days of insider sells: $425.0K by 2 insiders, avg $72.03
- Nov 5 ▲ ANI Pharmaceuticals reported Q3 2026 revenue of $290.8M (+27.6% YoY)…
- Nov 13 to Nov 18 ▼ 3 days of insider sells: $420.0K by 2 insiders, avg $71.18
Signal stack
Where each data set points today.
- InsidersBEARISH
10 insiders sold $11.8M.
- InstitutionsMIXED
Q3 2026: 23 added (0 new), 33 trimmed or exited.
- AnalystsBULLISH
12 of 15 rate it Buy or better. Every target is above the price.
- EstimatesFALLING
Current-quarter EPS estimate $2.853 → $2.559 over 90 days. 0 up, 5 down in 30 days.
- Short sellersSTEADY
Short interest +3.2% to 3.58M shares. 11.9 days to cover, ≈15.8% of shares.
- TrendDOWNTREND
5% below its 50-day average.
Who's buying
13F· Q3 2026| Fund | Move | Value |
|---|---|---|
| AMERICAN CENTURY COMPANIES INC | ADD | $66.3M |
| UBS Group AG | DOUBLED | $45.1M |
| VICTORY CAPITAL MANAGEMENT INC | DOUBLED | $25.1M |
| MILLENNIUM MANAGEMENT LLC | TRIM | $17.7M |
| HOTCHKIS & WILEY CAPITAL MANAGEMENT LLC | DOUBLED | $14.8M |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | DOUBLED | $12.3M |
| Schonfeld Strategic Advisors LLC | DOUBLED | $9.7M |
| Man Group plc | ADD | $8.2M |
Quarterly 13F filings are due 45 days after each quarter ends.
The Street
15 analystsPrice is below the lowest target. Median implies +49%.Targets as of Nov 22, 2026.
| Date | Firm | Rating |
|---|---|---|
| Nov 6, 2026 | Guggenheim MAINTAIN | Buy |
| Sep 23, 2026 | Oppenheimer INITIATE | Perform |
| Aug 10, 2026 | Guggenheim MAINTAIN | Buy |
| Aug 10, 2026 | Canaccord Genuity MAINTAIN | Hold |
| Jul 17, 2026 | Canaccord Genuity INITIATE | Hold |
| Jul 10, 2026 | Guggenheim REITERATE | Buy |
Insider ledger
Form 4| Insider | Type | Value |
|---|---|---|
Lalwani Nikhil PRESIDENT & CEO Nov 18, 2026 | SELL | $290.5K |
Lalwani Nikhil PRESIDENT & CEO Nov 16, 2026 | SELL | $94.1K |
Cook Meredith SR. VP, GENERAL COUNSEL & SEC. Nov 13, 2026 | SELL | $35.4K |
CAREY STEPHEN P. SVP & CFO Oct 29, 2026 | SELL | $207.7K |
Lalwani Nikhil PRESIDENT & CEO Oct 15, 2026 | SELL | $388.2K |
Cook Meredith SR. VP, GENERAL COUNSEL & SEC. Oct 13, 2026 | SELL | $36.8K |
CAREY STEPHEN P. SVP & CFO Sep 29, 2026 | SELL | $208.1K |
Lalwani Nikhil PRESIDENT & CEO Sep 15, 2026 | SELL | $383.4K |
Earnings setup
Estimates| Period | EPS est. | Range | 30D rev. | Revenue |
|---|---|---|---|---|
| Current Q | $2.56 | $2.41–$2.66 | -9.2% | $305.3M |
| Next Q | 🔒 Fresh data, subscribers only | |||
| Current FY | 🔒 Fresh data, subscribers only | |||
| Next FY | 🔒 Fresh data, subscribers only | |||
Short side
FINRA· Oct 30, 2026SecBot reports
28 filings · 6 press releases · 6 bullish · 3 bearish · 1 mixed · 18 neutral- NEUTRAL CLUSTERNov 18, 2026
CEO Nikhil Lalwani and SVP Meredith Cook sold shares totaling $130K in open-market transactions…
The sales are small and pre-planned, carrying no new signal. Monitor for any insider purchases or larger non-10b5-1 sales post-acquisition close.
- NEUTRAL 144Nov 16, 2026
CEO Nikhil Lalwani filed a Form 144 notice to sell 5,400 shares of ANI Pharmaceuticals common…
The CEO's Form 144 is consistent with a pre-arranged 10b5-1 trading plan, as evidenced by identical monthly sale volumes in prior months. No new directional signal; monitor for any change in pattern…
- NEUTRAL 8-KNov 16, 2026
ANI Pharmaceuticals published an updated November 2026 investor presentation reaffirming its 2026…
Monitor the Egetis Therapeutics tender offer acceptance period (expected Nov 20 to Dec 18, 2026) for closing conditions, including the 90% shareholder acceptance threshold. Track upcoming quarterly…
- MIXED INST-CLUSTERNov 9, 2026
Institutional 13F cluster for ANIP in Q3 2026 shows mixed conviction: 4 small asset managers added…
The selling is concentrated among larger holders while buying comes from small advisors, suggesting a rotation rather than a uniform thesis. Monitor upcoming 13F filings for Q4 to see if the selling…
All ANIP filing & press-release reports (34)
- CLUSTER reportNov 18, 2026
- 144 reportNov 16, 2026
- 8-K reportNov 16, 2026
- INST-CLUSTER reportNov 9, 2026
- 8-K reportNov 5, 2026
- 8-K reportNov 5, 2026
- PRESS-RELEASE reportNov 5, 2026
- PRESS-RELEASE reportNov 5, 2026
- PRESS-RELEASE reportNov 5, 2026
- 144 reportOct 29, 2026
- CLUSTER reportOct 16, 2026
- PRESS-RELEASE reportSep 23, 2026
- CLUSTER reportSep 16, 2026
- CLUSTER reportSep 14, 2026
- CLUSTER reportSep 1, 2026
- 8-K reportAug 24, 2026
- CLUSTER reportAug 13, 2026
- 8-K reportAug 7, 2026
- COURT-RULING reportJul 16, 2026
- PRESS-RELEASE reportJul 13, 2026
- CLUSTER reportJun 15, 2026
- CLUSTER reportJun 10, 2026
- 8-K reportMay 21, 2026
- CLUSTER reportMay 11, 2026
- 8-K reportMay 13, 2026
- 8-K reportMay 8, 2026
- PRESS-RELEASE reportMay 8, 2026
- PRESS-RELEASE reportApr 24, 2026
- PRESS-RELEASE reportApr 8, 2026
- 8-K reportApr 7, 2026
- PRESS-RELEASE reportApr 7, 2026
- CLUSTER reportMar 9, 2026
- CLUSTER reportMar 3, 2026
- CLUSTER reportMar 3, 2026